Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Fujiwara

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Cancer Reports (Hoboken, N.J.)|December 9, 2020
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patientsNaoki Fukuda, Mayu Yunokawa, Yu Fujiwara, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
Adverse events induced by nivolumab and ipilimumab combination regimensKohei Somekawa, Nobuyuki Horita, Ayami Kaneko, et al.
Cancer Management and Research|November 19, 2021
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received ChemoradiotherapyNaomi Hayashi, Yasuyoshi Sato, Yu Fujiwara, et al.
JCO Precision Oncology|November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-AnalysisJonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.
Cancer Medicine|April 9, 2025
Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II StudySarbajit Mukherjee, Yu Fujiwara, Christos Fountzilas, et al.
Cancer Cell|October 16, 2020
Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer HospitalYu Fujiwara, Yasuyoshi Sato, Xiaofei Wang, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Cancer Reports (Hoboken, N.J.)|December 9, 2020
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patientsNaoki Fukuda, Mayu Yunokawa, Yu Fujiwara, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
Adverse events induced by nivolumab and ipilimumab combination regimensKohei Somekawa, Nobuyuki Horita, Ayami Kaneko, et al.
Cancer Management and Research|November 19, 2021
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received ChemoradiotherapyNaomi Hayashi, Yasuyoshi Sato, Yu Fujiwara, et al.
JCO Precision Oncology|November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-AnalysisJonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.
Cancer Medicine|April 9, 2025
Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II StudySarbajit Mukherjee, Yu Fujiwara, Christos Fountzilas, et al.
Cancer Cell|October 16, 2020
Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer HospitalYu Fujiwara, Yasuyoshi Sato, Xiaofei Wang, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 7